Skip to main content

Seaport Therapeutics, Inc 10-Q for FY2026 Q3

Seaport Therapeutics, Inc. (SPTX)

10-Q 2026-11-02 For: 2026-09-30
View Original
Added on November 02, 2026

About this 10-Q

Seaport Therapeutics, Inc filed this 10-Q on November 2, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Seaport Therapeutics reported a $114.4 million nine-month net loss and $403.8 million in cash, cash equivalents and investments, which management believes will fund operations into 2029 after its IPO. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$26.39M
compared with a net loss of $22.54M a year earlier
Diluted EPS
-$0.49
compared with -$9.43 a year earlier